Reference
Larussa T, et al. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a singlecentre prospective case series. Medicine and Pharmacy Reports 94: 289-297, No. 3, Jan 2021. Available from: URL: https://medpharmareports.com/index.php/mpr/article/view/1897
Rights and permissions
About this article
Cite this article
Adalimumab/golimumab/infliximab. Reactions Weekly 1905, 18 (2022). https://doi.org/10.1007/s40278-022-14408-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-14408-6